Therefore, we now consider CDK12 an upstream factor in the BRCA and HR gene response pathway, and CDK12 mutations, as well as BRCA mutations, can be therapeutically used to predict the sensitivity to PARP inhibitors in cancer treatment. The gene discussed is PARP1; the disease is cancer.